Ronald Asbury Andrews, Director and Chief Business Officer of Cerenome, Inc., filed a Form 4 on November 10, 2026, disclosing the acquisition of stock options covering 92,858 shares of common stock on November 9, 2026.

Key Highlights

  • Reporting person: Ronald Asbury Andrews, serving as Director and Chief Business Officer of Cerenome, Inc. (NASDAQ:CNSY)
  • Transaction date: November 9, 2026, with the form signed by attorney-in-fact Andrew Sims on November 10, 2026
  • Securities acquired: 92,858 stock options (right to buy) with an exercise price of $0.57 per share
  • Price of derivative security: $0 at grant
  • Expiration date: November 8, 2036
  • Beneficial ownership following transaction: 92,858 derivative securities, held directly
  • Vesting schedule: 48 monthly installments, with 50% vesting over the first 12 months and the remaining 50% vesting over the following 36 months

Option Grant Details for Andrews at Cerenome, Inc.

According to the filing, Andrews acquired stock options granting the right to buy 92,858 shares of Cerenome, Inc. common stock at an exercise price of $0.57. The transaction was coded "A" (acquired) and recorded under Table II covering derivative securities. The price of the derivative security at grant is reported as $0, and the options are held directly by the reporting person.

The filing discloses that the options expire on November 8, 2036, and vest according to a 48-month schedule. As described in the explanation of responses, "fifty percent (50%) of the shares subject to the Option will vest in twelve (12) equal monthly installments during the first twelve (12) months following the Grant Date, beginning on the one-month anniversary of the Grant Date," with "the remaining fifty percent (50%) of the shares subject to the Option will vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."

Following the reported transaction, Andrews is listed as beneficially owning 92,858 derivative securities in total, all held in direct ownership form. The filing was submitted by Andrew Sims as attorney-in-fact on behalf of Andrews.

What Was Disclosed

Cerenome, Inc. Director and Chief Business Officer Ronald Asbury Andrews reported the acquisition of 92,858 stock options at an exercise price of $0.57, granted November 9, 2026, expiring November 8, 2036, and vesting over 48 monthly installments.